Literature DB >> 8276018

The management of chronic granulomatous disease.

A Fischer1, A W Segal, R Seger, R S Weening.   

Abstract

Chronic granulomatous disease (CGD) is a primary immunodeficiency disease which results from absence of the NADPH oxidase in the professional phagocytic cells neutrophils, monocytes, macrophages and eosinophils. Deficiency of this oxidase renders the patient liable to infection by bacteria and fungi, and, as the name of the disease suggests, to chronic granulomatous inflammation. These patients present with a great variety of infections and other complications of their disease, which often tax the clinical and therapeutic skill of the doctors responsible for their care. Collectively we look after, or advise on the management of, over 100 of these subjects, and have developed experience in the diagnosis and management of the infections and other clinical problems they present. We thought that it might be timely to provide guidelines for their management based upon this experience. The numbers of patients are still relatively small, and the clinical presentations very varied, so it is impossible to provide clear statistical proof of the veracity of this advice. It does, however, reflect the working practise of the physicians caring for many of these patients in Europe.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8276018     DOI: 10.1007/bf01957525

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  15 in total

1.  Interferon gamma for chronic granulomatous disease.

Authors:  R Mouy; R Seger; J P Bourquin; F Veber; S Blanche; C Griscelli; A Fischer
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

2.  Induction of neutrophil FC-gamma receptor I expression can be used as a marker for biologic activity of recombinant interferon-gamma in vivo.

Authors:  T W Huizinga; C E Van der Schoot; D Roos; R S Weening
Journal:  Blood       Date:  1991-05-01       Impact factor: 22.113

3.  Incidence, severity, and prevention of infections in chronic granulomatous disease.

Authors:  R Mouy; A Fischer; E Vilmer; R Seger; C Griscelli
Journal:  J Pediatr       Date:  1989-04       Impact factor: 4.406

4.  Intracellular bactericidal effects of rifampicin in both normal and chronic ganulomatous disease polymorphs.

Authors:  G Ezer; J F Soothill
Journal:  Arch Dis Child       Date:  1974-06       Impact factor: 3.791

5.  Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi.

Authors:  M S Cohen; R E Isturiz; H L Malech; R K Root; C M Wilfert; L Gutman; R H Buckley
Journal:  Am J Med       Date:  1981-07       Impact factor: 4.965

6.  Chronic granulomatous disease: effect of sulfamethoxazole/trimethoprim on neutrophil microbicidal function.

Authors:  R A Seger; S Baumgartner; L X Tiefenauer; F K Gmünder
Journal:  Helv Paediatr Acta       Date:  1981

7.  Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma.

Authors:  R A Ezekowitz; M C Dinauer; H S Jaffe; S H Orkin; P E Newburger
Journal:  N Engl J Med       Date:  1988-07-21       Impact factor: 91.245

8.  Recombinant human interferon-gamma reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood.

Authors:  J M Sechler; H L Malech; C J White; J I Gallin
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

9.  Prolonged recombinant interferon-gamma therapy in chronic granulomatous disease: evidence against enhanced neutrophil oxidase activity.

Authors:  R C Woodman; R W Erickson; J Rae; H S Jaffe; J T Curnutte
Journal:  Blood       Date:  1992-03-15       Impact factor: 22.113

10.  Chronic granulomatous disease: uptake and intracellular activity of fosfomycin in granulocytes.

Authors:  P H Höger; R A Seger; U B Schaad; W H Hitzig
Journal:  Pediatr Res       Date:  1985-01       Impact factor: 3.756

View more
  10 in total

Review 1.  Neutrophil disorders and their management.

Authors:  R Lakshman; A Finn
Journal:  J Clin Pathol       Date:  2001-01       Impact factor: 3.411

2.  Colitis in chronic granulomatous disease.

Authors:  M G Schäppi; V V Smith; D Goldblatt; K J Lindley; P J Milla
Journal:  Arch Dis Child       Date:  2001-02       Impact factor: 3.791

3.  Bone marrow transplantation in chronic granulomatous disease.

Authors:  M C Calviño; M S Maldonado; E Otheo; A Muñoz; J M Couselo; C Burgaleta
Journal:  Eur J Pediatr       Date:  1996-10       Impact factor: 3.183

4.  Follow up of patients with chronic granulomatous disease diagnosed since 1990.

Authors:  C M Cale; A M Jones; D Goldblatt
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

5.  Diagnostic and therapeutic impact of whole body positron emission tomography using fluorine-18-fluoro-2-deoxy-D-glucose in children with chronic granulomatous disease.

Authors:  T Güngör; I Engel-Bicik; G Eich; U V Willi; D Nadal; J P Hossle; R A Seger; H C Steinert
Journal:  Arch Dis Child       Date:  2001-10       Impact factor: 3.791

6.  Long-term follow-up and prognosis of chronic granulomatous disease in Yugoslavia: is there a role for early bone marrow transplantation?

Authors:  Srdjan Pasic; Aleksandra Minic; Predrag Minic; Dobrila Veljkovic; Desa Lilic; Bojana Slavkovic; Nada Pejnovic; Mario Abinun
Journal:  J Clin Immunol       Date:  2003-01       Impact factor: 8.317

Review 7.  Clinical immunology review series: an approach to the patient with recurrent superficial abscesses.

Authors:  S L Johnston
Journal:  Clin Exp Immunol       Date:  2008-04-16       Impact factor: 4.330

8.  Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry.

Authors:  L B K R Jones; P McGrogan; T J Flood; A R Gennery; L Morton; A Thrasher; D Goldblatt; L Parker; A J Cant
Journal:  Clin Exp Immunol       Date:  2008-05       Impact factor: 4.330

9.  The role of surgery in the management of patients with refractory chronic granulomatous disease colitis.

Authors:  Melissa M Alvarez-Downing; Natasha Kamal; Suzanne M Inchauste; Sajneet K Khangura; Harry L Malech; Steven M Holland; Marybeth S Hughes; Theo Heller; Richard M Sherry
Journal:  Dis Colon Rectum       Date:  2013-05       Impact factor: 4.585

10.  The discovery of agammaglobulinaemia in 1952.

Authors:  Walter H Hitzig
Journal:  Eur J Pediatr       Date:  2003-03-01       Impact factor: 3.860

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.